{"entity":{"id":"nct07589517","kind":"trial","name":"Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer","aka":[],"tldr":"A phase 1/2 trial of EB-DUO-CAR-NK-CEA/GCC in colorectal cancer, run by Beijing Biotech, now recruiting.","summary":"Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer is a phase 1/2 interventional study registered as NCT07589517 by Beijing Biotech, with 48 participants planned, started 2026-02-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-DUO-CAR-NK-CEA/GCC and Lymphodepletion.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07589517","url":"https://clinicaltrials.gov/study/NCT07589517"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07589517","phase":"1/2","setting":"A Phase 1/2, Biomarker-Assigned, Open-Label Dose Escalation and Expansion Study of Allogeneic Dual-Target CAR-NK Cells Targeting CEA (CEACAM5) and/or GUCY2C (GCC) With an Exploratory HER2/ERBB2-Positive Cohort in Subjects With Advanced or Metastatic Colorectal Cancer","sponsor":"Beijing Biotech","enrolled":48,"outcomes":[]},"route":"/trials/nct07589517/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}]}}